Biotech Daily

Friday August 28, 2026

Daily news on ASX-listed biotechnology companies

*** ASX UP, BIOTECH DOWN: CLARITY UP 7%; SALUDA DOWN 24%**

*** DR BOREHAM'S CRUCIBLE: CONTROL BIONICS**

*** SALUDA REVENUE UP 28% TO $125m; LOSS FLAT AT $207m**

*** SOMNOMED REVENUE UP 3% TO $115m; LOSS DOWN 23% TO $3m**

*** AUSTCO RECORD REVENUE UP 16% TO $94m; PROFIT UP 52% TO $9m**

*** IMEX H1 REVENUE UP 17% TO $16m; $3m LOSS TO $66k PROFIT**

*** MACH7 REVENUE DOWN 17% TO $28m; LOSS UP 44% TO $10m**

*** RESONANCE REVENUE UP 42% TO $16m; $2m LOSS TO $1.5m PROFIT**

*** MICRO-X REVENUE UP 16% TO $15m; LOSS DOWN 29% TO $10m**

*** HYDRIX REVENUE DOWN 3.5% TO $10m; LOSS UP 84% TO $7m**

*** IMMURON REVENUE UP 6% TO $8m; LOSS DOWN 27% TO $4m**

*** 4D MEDICAL REVENUE UP 21% TO $7m; LOSS DOWN 7% TO $33m**

*** CONTROL BIONICS REVENUE DOWN 22% TO $5m; LOSS UP 19% TO $7m**

*** MINOMIC SEEKS $7m FOR MICHECK PROSTATE CANCER BLOOD TEST**

*** AUSCELERATE SIGNS SHANGHAI LIFE SCIENCES COLLABORATION**

*** WEHI: 'EARLY INFLAMMATORY BOWEL DISEASE WARNING SIGNS'**

*** IMRICOR, PHILIPS LAUNCH INTERVENTIONAL CARDIAC MR PRODUCT**

*** MEMPHASYS WINS THAI FELIX IVF APPROVAL**

*** PATRYS PHASE Ia RLS-2202 DELIRIUM TRIAL ETHICS APPROVAL**

*** PERCHERON HMBD-002 LEUKAEMIA TRIAL; TRADING HALT**

*** AMPLIA AGM 22% OPPOSE PLACEMENT FACILITY**

*** PINNACLE TAKES 5% OF COCHLEAR**

*** WASHINGTON H SOUL PATTINSON TAKES 6% OF IMUGENE**

*** MERCER BELOW 5% OF GENETIC SIGNATURES**

*** MARK AZZI TAKES 11% OF NYRADA**

MARKET REPORT

The Australian stock market was up 0.6 percent on Friday August 28, 2026, with the ASX200 up 54.1 points to 9,092.3 points. Fourteen of the Biotech Daily Top 40 companies were up, 17 fell and nine traded unchanged. The four Big Caps were mixed.

Clarity was the best, up 17 cents or 7.3 percent to $2.51, with 2.8 million shares traded. Atomo, Botanix and Paradigm climbed five percent or more; Actinogen was up 4.8 percent; Imricor, Mesoblast and Nanosonics rose more than two percent; Alcidion, Aroa, Cyclopharm, Medical Developments, Polynovo, Pro Medicus and Resmed were up one percent or more; with Telix up by 0.45 percent.

Saluda led the falls (see below), down 15.5 cents or 24.4 percent to 48 cents, with 4.7 million shares traded. Resonance lost 12.3 percent; Curvebeam was down 10 percent; Clinuvel shed 7.7 percent; Dimerix was down 5.2 percent; Artrya and Racura fell more than four percent; Amplia, Emvision, Micro-X, Nova Eye and Syntara were down more than three percent; Neuren shed 2.7 percent; Avita, Cochlear, EBR, Imugene and Prescient were down more than one percent; with CSL down by 0.9 percent.

DR BOREHAM'S CRUCIBLE: CONTROL BIONICS

By TIM BOREHAM

ASX code: CBL

Share price: 5.8 cents; **Shares on issue:** 445,317,670; **Market cap:** $25.8 million

Chief executive officer: Jeremy Steele

Board: Stephen Rix (chair), Mr Steele, Damian Lismore, Prof Robert Heard, Prof Nicholas Opie

Financials (Year to June 30, 2026): receipts $5.3 million, net cash outflows $5.7 million, June 30, 2026 cash $2.1 million (ahead of $7.25 million from second tranche of capital raising)

Major shareholders: Nightingale Partners 19.2%, Phoenix Development Fund 16.5%, Reitham Equity GmbH 13.89%

With a background in investment banking, Control Bionics CEO Jeremy Steele appreciates the commercial realities of gaining a foothold in the US medical device market. That is: it's not easy.

Initially, the company took a direct-to-retail, do-it-yourself (DIY) approach with its assistive communication tool, Neuronode.

Based on surface electro-myography (EMG), Neuronodes are watch-sized, wireless, neuro-electric sensor enabling people with disabilities to use their own ‘brain-to-muscle’ electrical signals to control communication and movement.

“When I joined the company three and a bit years ago it was a retail business,” Mr Steele says. “We were packaging up technology and selling it effectively directly to the end consumer.”

The business grew to a handy $6 million a year turnover – slightly more than the company’s run rate for the 2025-’26 year. But the “market realities” became apparent, he says.

“Particularly in the US, you rely on the insurance regime to be able to make the business work. It was clear to me it was going to be very difficult for us to scale without investing enormous amounts of money.”

The solution?

Control Bionics has opted to sell through large, specialist partners with a streamlined route through often byzantine insurance payment channels.

At the start of the year the company signed up its two biggest partners: Tobii Dynavox and PRC-Saltillo. With a combined salesforce of 250 people, these parties specialize in assistive communications products.

“Not only do we have the advantage of the scale of their sales reps, but their in-network contracts mean they get paid more quickly - and they sell more,” Mr Steele says.

Off its own bat, the company might have to wait one to three months - or even longer - to get paid.

In the meantime, Control Bionics has found a bigger opportunity for a product variant called Neurostrip, for the sports performance and rehabilitation sectors (see below).

Neurostrips measure physiological data such as unintentional muscle movements.

What a good idea

Based in Melbourne’s technology hub of Cremorne (near Richmond), Control Bionics was founded in 2005 by Queenslander Peter Ford, a computer scientist and technology broadcaster on the US network CNN.

In 2014, Control Bionomics acquired Therapeutic Alliances of the US, which owned key patents over electro-myography monitors. Backed by local ‘angel’ investors, the company listed on the ASX in December 2020, having raised $15 million at 60 cents apiece.

A former marketer, Rob Wong joined as CEO in January 2017 but resigned in September 2022, owing to poor health.

He was replaced by Mr Steele, who has expertise in the healthcare, software, financial services and retail sectors.

The US Food and Drug Administration approved Neuronode in 2020.

In December 2024, the company attained crucial US Healthcare Common Procedure Coding System (HCPCS) coverage. The reimbursement code - E2513 if you must know - locks in a rate of $US4,300 ($A5,988) per device.

This month, the FDA registered and listed the Neurostrip platform as a medical device.

Strictly speaking, Control Bionics doesn't need this imprimatur for the sports and rehab markets, but it helps with the street cred.

Neuronode explained

Electro-myography (EMG) is about capturing and processing neuro-electric signals into electronic commands. The technology enables a person to control a cursor with their eyes and then select an item from where the cursor lands.

Neuronode involves 'tapping' the neural (or visual) signals, as sent from the brain to the muscles.

A finger movement happens because the brain sends a signal to a muscle. The muscles don't have to be functioning; as long as the electrical signals exist. Users include those with motor neuron disease, spinal cord injuries, cerebral palsy and multiple sclerosis.

Neuronode uses algorithms to convert the body's neuro-electric signals into code, which controls the devices. The algorithms are the company's 'secret sauce'.

Other rival assistive technology devices require a keyboard, mouse, joystick, touch screen or eye-tracking to function.

Neuronode3 combines Neuronode with speech-generating software, while Neuronode Trilogy combines Neuronode with eye-tracking technology. The device attaches anywhere on the body where the user has intentional control.

For instance, a person with deteriorating motor neuron disease might start with the device on their wrist, then a toe or even an eyebrow.

Neurostrip explained

A miniaturized version of Neuronode, Neurostrips measure physiological data such as unintentional muscle movements.

While based on the same technology, Neurostrip is a "very different business" to Neuronode.

Apart from targeting different markets, Neurostrip is sold on a software-as-a-service basis.

“Importantly it generates a lot of data that can be used by existing customers and for future third-party uses,” Mr Steele says.

Locally, Control Bionics has signed up the Australian Football League clubs Greater Western Sydney - a foundation customer - and Hawthorn.

The company has National Rugby League clubs Brisbane Broncos on its books, as well as Australian Rugby and the Australian Institute of Sport.

“The clients are using the tech in different ways,” Mr Steele says.

These customers pay a fee to buy the equipment and then a software fee. Varying between $US3,500 ($A4,872) a year and “north of $US20,000”, the cost depends on how the clients use the devices and how many devices they adopt.

The biggest Neurostrip customer to date, Ohio University, has about 30 devices and might end with 100 units.

Local use tends to be about injury management, while in the US it’s more about performance (for example, establishing a baseline level of muscle activation).

“The beauty is that once the technology is in there, the club can use it for whatever they want,” Mr Steele says.

Go to rehab? Yes, yes, yes

While Australians and Americans love to talk about sport, on pure numbers the rehabilitation opportunities for Neuronode are more significant than the athletic side.

In the US, the company has signed about half a dozen rehabilitation groups and has started rolling out Neurostrip in the UK.

Demand has exceeded management’s expectations.

The company believes about 50 percent of rehabilitation patients could benefit from surface electro-myography (EMG).

Physiotherapist practices are another potentially fertile source of custom, given pain and muscle movement measures can be highly subjective.

Mr Steele says the science of surface EMG does not need to be proven in a rehabilitation context.

“We're not [presenting] some new-fangled technology. Plenty of clinical research has been done over years and years.”

However, physiotherapists haven't embraced EMG because it has not been efficient or effective enough.

A physiotherapy session might last half an hour, so if the device takes 15 minutes to attach, the clinician won't use it.

"Our system can be attached to the skin in about three minutes."

Germany beckons

Neuronode devices are approved in the US, European Union, Canada, Australia and – as of this week - the UK.

Outside the US, Control Bionics is focused on entering Germany, the world's second largest assistive communications market by value.

The company should announce its first German distributor imminently, with a launch "in the coming weeks".

Neuronodes have been listed on Germany's Statutory Health Insurance Medical Aids Directory. This confers reimbursement similar to HCPCS in the US.

"It's a compelling opportunity," Mr Steele says. "But we will need to work with our German partners to develop demand."

The company is also tackling Japan, where the products don't need to be approved.

She'll be Apples

Control Bionics also is selling products called Next Level; with Apple Ipads infused with the company's technology.

Apple has conferred the company has the exclusive rights to the devices, which are compatible with Apple's new Brain-Computer Interface (BCI) and Human Interface Device (HID) protocols.

Mr Steele says Neuronode suits complex conditions such as motor neuron disease.

"It is low volume, high value market".

Users don't have the ability to touch a screen. Then there's a separate market for children with autism and other special needs.
"These children are using devices to communicate by touching with their fingers, rather than using Neuronode [and eye gaze technology] to connect to it."

In the US, about one million such devices are sold each year.

“We were approached by one of our existing customers who was looking to change from their existing supplier and wanted to work with us instead,” Mr Steele says.

“We partnered and got access to, or licenced, some innovate designs.”

Control Bionics has signed a letter of intent with an unnamed customer, who has paid a $US100,000 deposit for 1,000 devices over 12 months. The tablets cost around $US3,000 each, wholesale.

The company is pursuing US Medicare approval for the tablets.

Mr Steele describes Next Level as a “margin opportunity” the company will confine to the US market.

Once the Next Levels are launched in the current quarter, they should generate “meaningful revenue” as Neurostrip turnover builds more slowly.

Finances and performance

Control Bionics reported June (fourth) quarter receipts of $1 million, taking the 2025-26 financial year tally to $5.28 million.

This largely reflected Neuronode sales, with about 80 percent of revenue deriving from the US.

Mr Steele says the flat quarterly number partly reflected the company’s transition from a retail to wholesale model.

“We've scaled back retail as we build wholesale, but the timing [of revenue] hasn’t matched exactly as we had hoped.”

He says management expects “material revenue growth” in the current financial year. In June, for the first time, monthly wholesale revenue exceeded retail turnover.

The company reported June quarter net cash outflows of $1.6 million, with a full-year deficit of $5.7 million.

In June, the company announced a $9.5 million placement, in two tranches of $2.25 million and $7.25 million. Shareholders approved the latter at a meeting this month, while the company also raised $250,000 in a share purchase plan.

The raising was done at 7.5 cents per share, a 14.5 percent discount.

Over the last year Control Bionomics shares have vacillated between 3.2 cents (late October last year) and 9.3 cents (early June this year).

The stock peaked at $1.24 on listing day.

Can someone clean up the NDIS-mess?

Control Bionics' local prospects have been held back by ongoing problems with accessing National Disability Insurance Scheme (NDIS) funding for Neuronode.

About 90 percent of local Neuronode sales are NDIS funded and the company has $1.1 million of customer receipts awaiting approval or submission.

The Federal Government is determined to rein-in the ballooning cost of the NDIS – and the company appears to be a victim.

Dr Boreham's diagnosis:

Mr Steele says he knows that Neurostrip is hitting the spot because athletes have asked how they can buy the company's shares.

"These are people who understand the importance of being able to improve their performance," he says.

On the sporting side, if anything, the company is competing with other non-electro-myography wearables that assess performance.

With Neuronode, Mr Steele says the new distributors are "finding ways to engage with clients they've not been able to [access] before, because our technology is unique and we are the only ones with an HCPCS code."

But an "impatient" Mr Steele rues the Neuronode rollout is "just not going fast enough".

"The reality is that by definition the industry has long sales cycles," he says. "We're dealing with individuals with compromised needs; that means they can't do everything as quickly as you'd like them to. "We also deal with an insurance regime that is slow to move."

Impatient shareholders may have heard it before, but the next 12 or so shape up as a seminal period as the company's US distributor sales ramp up.

Then there's Neurostrip, which is likely to be a bigger opportunity than Neuronode.

The company cites a $US1 billion market size for the Neuronodes. The Neurostrip lands at $US2 billion for sport and $US2.2 billion for rehabilitation.

"The demand clearly is there," Mr Steele says.

"As we build demand, people will come to us".

Dr Boreham is not a qualified medical practitioner. He does not possess a doctorate of any sort because he was too impatient to stay the course; and the demand wasn't sufficient.

SALUDA MEDICAL

Saluda says revenue for the year to June 30, 2026 was up 28.2 percent to $US90,175,000 ($A125,256,000), with net loss after tax flat at $US148,835,000 ($A206,796,000).

Last year, the Bloomington, Minnesota-based Saluda fell as much as 52.45 percent to $1.26 following its $230.8 million ASX initial public offer at $2.65 a share to commercialize its Evoke spinal cord simulation for pain relief; and at the time, said it expected revenue for the year to June 30, 2026 of about $US81.9 million (BD: Dec 5, 2025).

Today, the company said its increased revenue was “driven by continued commercial execution in the US, including expansion of the company's active implanting physician base, increased physician utilization, growth in implanted patients and the continued maturation of the company's trained sales force”.

Saluda said non-US revenue increased compared to the prior corresponding period, supported by continued customer demand in Europe and Australia.

The company said its loss reflected “continued investment in its commercial infrastructure, including expansion of the US sales organization, physician education initiatives, and activities to support future growth”.

Saluda said diluted loss per share fell 80.9 percent from $US459.19 in the prior year to $US14.78, with net tangible asset backing per share turned from a negative $US324.38 to a positive $US2.17.

The company said it had 325,145 shares on issue in the year to June 30, 2025, pre-initial public offer, and a post-IPO 16,215,873 shares on issue.

Saluda said it had cash and cash equivalents of $US116,377,000 at June 30, 2026 compared to $US54,500,000 at June 30, 2025.

Saluda fell 15.5 cents or 24.4 percent to 48 cents with 4.7 million shares traded.

SOMNOMED

Somnomed says revenue for the year to June 30, 2026 was up 2.7 percent to $114,532,000, with net loss after tax down 23.3 percent to $2,650,000.

Somnomed said revenue was from sales of its Somnodent products for obstructive sleep apnoea, snoring, bruxism and other sleep-related breathing disorders.

The company said that “a change in the market dynamics in Europe and the significant appreciation of the Australian dollar during the second half of the year adversely affected revenue growth”.

Somnomed said Europe sales rose 0.8 percent to $61,942,000, with North America up 6.3 percent to $45,769,000 and Asia Pacific sales down 2.75 percent to $6,821,000.

The company said sales and marketing expenses were even at $22,993,000, research and development expenses rose 6.8 percent to $17,352,000 and share-based payment losses were up 86.1 percent to $3,623,000 with an unrealized foreign exchange loss of $1,057,000 compared to $77,000 in the prior year.

Somnomed said it entered 2026-’27 with “a clear focus on restoring stronger growth while progressively expanding profitability through product innovation, broader market access and disciplined commercial execution”.

In 2024, the company said its net tangible asset backing per share was 10.0 cents, with no figure disclosed in the year to June 30, 2025 nor this year (BD: Aug 28, 2024).

Somnomed said that diluted loss per share fell 25.15 percent to 1.22 cents and that it had cash and cash equivalents of $17,184,000 at June 30, 2026 compared to $17,293,000 at June 30, 2025.

Somnomed was up half a cent or 1.5 percent to 33.5 cents.

AUSTCO HEALTHCARE

Austco says record revenue for the year to June 30, 2026 was up 15.8 percent to $94,242,000, with net profit after tax up 51.8 percent to $9,004,000.
Austco said revenue from sales of its Tacera and Pulse nurse call and communications software and clinical workflow systems was “driven by both organic growth in existing operations and a full year’s revenue from [Guild & Spence], the latest acquisition.”
Last year, the company said it acquired Auckland’s Nurse Call reseller Guild & Spence Technologies for $NZ7,966,035 (BD: May 30, 2025).
Today, Austco said its profit represented “compound growth over the past three years, underpinned by both revenue expansion and improved operating leverage, and highlights the benefits of … strategic initiatives and disciplined execution”.
The company said diluted earnings per share rose 48.8 percent to 2.384 cents, with net tangible assets per security including right of use up 52.0 percent to 8.24 cents.
Austco said that it had cash and cash equivalents of $16,277,000 at June 30, 2026 compared to $14,483,000 at June 30, 2025.
Austco was up 2.5 cents or 11.4 percent to 24.5 cents with 1.5 million shares traded.

IMEX HEALTH SERVICES

Imex says revenue for the six months to June 30, 2025 was up 16.8 percent to $15,949,464 with last year’s $3,004,720 net loss after tax turned to a $66,200 profit.
Imex said revenue was from sales and leasing agreements of its internet cloud-based medical imaging software and radiology services, with the “majority of the group’s revenue derived from one geographic region, Latin America”.
The company said software revenue rose 2.6 percent to $4,777,861 and services revenue was up 24.1 percent to $11,171,603, with a $1,784,485 impairment charge recognized during the prior corresponding period compared to no charge this period.
Imex said it had a 0.12 cents diluted earnings per share for the year compared to a diluted loss per share of 6.19 cents in the prior corresponding period, with net tangible assets per share down 23.6 percent to 18.73 cents.
The company said that it had cash and cash equivalents of $1,985,026 at June 30, 2026 compared to $2,495,030 at June 30, 2025.
Imex was unchanged at 35 cents.

MACH7 TECHNOLOGIES

Mach7 says revenue for the year to June 30, 2026 fell 17.35 percent to $27,909,143, with net loss after tax down 44.0 percent to $9,928,554.
Mach7 said revenue was lower “due to lower one-off capital software licence revenue, a reduction in recurring revenue and lower professional services” related to subscriptions, maintenance, support, and licencing for its Enterprise imaging software, diagnostic viewing and workflow applications and data management systems.
The company said increased additional and existing customers were “more than offset by the non-renewal of Trinity Health and the ceased Veteran’s Health Administration contract”.
Mach7 said diluted loss per share rose 46.15 percent to 3.8 cents, with net tangible assets per share down 18.4 percent to 8.0 cents.
The company said it had cash and cash equivalents of $19,920,095 at June 30, 2026 compared to $23,069,049 at June 30, 2025.
Mach7 was up one cent or 3.6 percent to 28.5 cents.

RESONANCE HEALTH

Resonance says revenue for the year to June 30, 2026 rose 42.25 percent to $15,751,909 with last year's $1,732,939 net loss turned to a $1,513,109 net profit after tax.
Resonance said revenue was from sales of its Ferriscan for liver iron analysis, Cardiac T2 for assessing iron in the heart, and Hepafat-Scan for monitoring liver as well as its clinical trials research business including the acquired Trialswest.
The company said revenue rose due to "strong demand in clinical trials in particular" as well as "a significant increase in demand for its liver disease related products".
Resonance said an income tax benefit of $413,631 contributed to its profit and that it continued to invest in research and development, business development, regulatory and quality affairs and customer services.
The company said last year's diluted loss per share of 0.38 cents was turned to a diluted profit per share of 0.31 cents, with net tangible assets per share turned from negative 0.22 cents to positive 0.12 cents.
Resonance said that it had cash and cash equivalents of $4,849,447 at June 30, 2026 compared to $2,976,570 at June 30, 2025.
Resonance fell 0.8 cents or 12.3 percent to 5.7 cents with 1.4 million shares traded.

MICRO-X

Micro-X says revenue for the year to June 30, 2026 was up 15.6 percent to $15,087,000, with net loss after tax down 28.9 percent to $9,876,000.
Micro-X said revenue from engineering and contract services fell 7.6 percent to $9.7 million, sales of its Rover mobile x-ray rose 107.7 percent to $5.4 million "driven by increased Rover Plus system sales including the record sale to the Malaysian Ministry of Health".
The company said loss reduction was "largely driven by increased product sales and the absence of the Argus impairments recognized in 2024-'25 following the discontinuation of the Argus product", its mobile bomb x-ray for defence applications.
Micro-X said diluted loss per share fell 38.2 percent to 1.41 cents, with net tangible assets per share down 40.35 percent to 0.68 cents.
The company said that it had cash and equivalents of $3,136,000 at June 30, 2026 compared to $3,242,000 at June 30, 2025.
Micro-X fell 0.1 cents or 3.85 percent to 2.5 cents with one million shares traded.

HYDRIX

Hydrix says revenue for the year to June 30, 2025 was down 3.5 percent to $9,741,433 with net loss after tax up 83.85 percent to $6,718,322.
Hydrix said the majority of revenue was from its medical technology consulting services as well as its Guardian heart device business, with the negative impact "primarily attributable to a temporary pause in Syncardia's Emporer program due to a change in their funding situation".
The company said its loss was "primarily attributable to … fee revenue decline … [and a] $2.3 million increase in non-cash, non-recurring losses on financial instruments".
The company said that diluted loss per share was down 34.8 percent to 1.86 cents, with negative net tangible assets per share down 78.0 percent to negative 0.56 cents.
Hydrix said it had cash and cash equivalents of $2,958,328 at June 30, 2026, compared to $914,274 at June 30, 2025.
Hydrix was unchanged at 0.35 cents with 6.3 million shares traded.

IMMURON

Immuron says revenue for the year to June 30, 2026 was up 5.85 percent to $7,713,601 with net loss after tax down 26.9 percent to $3,838,699.
Immuron said revenue was “primarily due to the sales increase in the Australian and North American markets for Travelan” and that it expected revenues from sales of Travelan for travellers’ diarrhoea product to continue to increase in the future.
The company said research and development expenses fell 46.25 percent to $1,933,400, with administrative and marketing costs in-line with the prior year.
Immuron said that diluted loss per share fell 42.9 percent to 1.29 cents, with net tangible assets per share down 2.9 percent to 3.35 cents.
The company said that it had cash and equivalents of $9,017,814 at June 30, 2026 compared to $2,830,526 at June 30, 2025.
Immuron was untraded at 3.7 cents.

4D MEDICAL

4D Medical says revenue for the year to June 30, 2026 was up 20.6 percent to $7,061,546 with adjusted net loss after tax down 6.6 percent to $32,934,109.
4D Medical said increase revenue from sales of its x-ray and computed tomography lung ventilation analysis software was “driven by strong commercial momentum across [business-to-business software-as-a-service] hospital and radiology partners, third party [artificial intelligence]-distributors and global medical technology companies”.
The company said a non-adjusted net loss of $203,020,956 including a non-cash expense relating to the increased equity value of the Pro Medicus loan to $164.6 million.
Last year, 4D Medical said it had a $10 million “hybrid debt and equity loan” from Pro Medicus at 12.5 percent annual interest and repayable in two years (BD: Aug 1, 2025).
The company said diluted loss per share rose 27.3 percent to 0.14 cents.
4D Medical said that last year’s negative 2.0 cent net tangible assets per share turned to a positive 17 cents.
The company said that it had cash and cash equivalents of $277,954,095 at June 30, 2026 compared to $6,878,735 at June 30, 2025.
4D Medical was unchanged at $3.64 with 5.6 million shares traded.

CONTROL BIONICS

Control Bionics says revenue for the year to June 30, 2026 fell 22.4 percent to $4,766,730, with net loss after tax up 18.9 percent to $7,265,603.
Control Bionics said revenue was from the sale of its assistive communications technology systems for the disability sector including its Neuronode and Neurostrip and Neurobounce for sports performance and rehabilitation.
The company said the decline in revenue was “primarily driven by continued delays in [National Disability Insurance Scheme] approvals in Australia, which constrained the conversion of customer orders into recognized revenue, and a slower-than-anticipated transition of the North American business from a direct retail model to a distributor-led wholesale model with key distribution partners”.
Control Bionics said diluted loss per share was down 15.15 percent to 1.96 cents, with net tangible assets per share down 20.0 percent to 0.44 cents.
The company said that it had cash and equivalents of $2,076,884 at June 30, 2026 compared to $594,733 at June 30, 2025.
Control Bionics fell 0.2 cents or 3.3 percent to 5.8 cents.

MINOMIC INTERNATIONAL LTD

Sydney's Minomic says it hopes to raise $US5 million ($A6.9 million) in 18 months to fund UK and US regulatory approval for its Micheck prostate cancer blood test.

Minomic said Micheck was a blood test being considered by physicians for prostate biopsy that provided with a risk score within 24-to-48 hours "allowing them to discharge with confidence, low-risk patients without a biopsy".

The company said Micheck showed "95 percent sensitivity and a 50 percent reduction in unnecessary biopsies validated across four independent studies" and used instruments already installed in most UK National Health Service laboratories.

Minomic told Biotech Daily that a study published in Urologic Oncology reported an 'area-under-the-curve' of 0.85, 95 percent sensitivity, 50 percent specificity and, in 358 evaluable patients, up to 50 percent of unnecessary biopsies could potentially be avoided.

An abstract of the study, titled 'Development and evaluation of the Micheck Prostate test for clinically significant prostate cancer' is at: https://pubmed.ncbi.nlm.nih.gov/37734979/.

Minomic said Micheck had been commercially available in the US since 2022 and Australia since 2023.

The company's website said Minomic chief executive officer was Sushmita Utpala, with David Burdis a director and chief financial officer, Dr Brad Walsh executive chair and Mark Kogos a director.

Minomic said it had signed a UK, Europe and Middle East commercialization agreement with the London-based Addaptive Group Holdings' subsidiary IDC Network in July 2026, as well as a clinical evaluation agreement for Micheck with the Manchester NHS Trust and Birmingham NHS Trust.

The company said it had begun the Conformité Européenne mark regulatory pathway, with "independent regulatory due diligence confirming a credible route to market".

Minomic said the capital raise was expected to be "the final private round before a planned ASX public listing targeted for 2027".

Ms Utpala said: "I genuinely believe Micheck is one of those rare things: both commercially compelling and genuinely good for people".

"Prostate cancer is killing 12,000 men in the UK every year, most of those deaths are preventable with earlier smarter detection," Ms Utpala said.

Investors should contact the chief financial officer: david.burdis@minomic.com.

Minomic is a public-unlisted company.

AUSCELERATE (FORMERLY MTP CONNECT)

Auscelerate says with the Shanghai Center of Biomedicine Development it will "build collaborative links and open-up … opportunities for Australian life science companies".

Auscelerate said it had signed a memorandum of understanding (MOU) with the Shanghai Center of Biomedicine Development for a three-year collaboration framework.

Auscelerate chief executive officer Stuart Dignam said the partnership aimed "to make a … difference in the way Australian … innovators engage with Shanghai.

"The MOU will support collaboration … over the next three years to match Australia's life sciences capabilities in research, early-stage drug discovery, [intellectual property] creation and clinical trials with China's high-level innovation and power in scaling and production," Mr Dignam said. "We will work on … programs and events including a talent exchange program, sci-tech exhibitions, roadshows and business matchmaking events while missions between Australia and Shanghai/China will also be supported."

Mr Dignam said Auscelerate would attend the Bio China biotechnology conference with Australian companies held from March 10 to 12, 2027 in Suzhou, China.

WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

The Walter and Eliza Hall Institute says early molecular warning signs of inflammatory bowel disease, which may improve prediction, monitoring and treatment.
WEHI said a study with the Royal Melbourne Hospital found a molecular defect in gut cells from people with inflammatory bowel disease, which involved abnormal cell death and was detectable in patients whose disease was well controlled.
The Institute said inflammatory bowel disease (IBD) included conditions such as Crohn's disease and ulcerative colitis, with symptoms including rectal bleeding, abdominal pain, diarrhoea, fatigue and weight loss.
WEHI said its research challenged "the idea that cell death in IBD is simply a consequence of inflammation, suggesting it may instead be part of the process driving disease", with the defect appearing in the earliest stages of disease activity, including in patients with clinically mild disease.
The Institute said the research, titled 'A necroptotic-to-apoptotic signaling axis underlies inflammatory bowel disease' was published in the journal Science, with an abstract available at: https://www.science.org/doi/10.1126/science.aeh7112.
WEHI said it collected about 900 biopsies from 80 individuals with and without IBD and then developed laboratory-grown tissues from patient samples to study IBD.
The Institute said it followed the patients for more than two years and "found that people with higher levels of intestinal cell death signalling were also more likely to relapse".
Study co-author Dr Jiyi Pang said the findings could help researchers develop more precise ways to monitor disease and, in the future, better match treatments to patients.

IMRICOR MEDICAL SYSTEMS

Imricor says with Philips it has launched a combined interventional magnetic resonance (IMR) laboratory product for advanced MR-guided cardiac interventions.
Imricor said the combined IMR laboratory product included Philips' high-performance 1.5 Tesla (1.5T) magnetic resonance imaging (MRI) platform and interventional workflow capabilities with Imricor's portfolio of MR-compatible systems and consumables.
Earlier this month, the company said that the Eindhoven, Netherlands-based Philips Medical Systems had issued a third-party product compatibility declaration covering its interventional MR products when used with Philips MR systems (BD: Aug 7, 2026).
Today, Imricor said the first commercially available configuration was designed to allow interventional MR-guided workflows for cardiac interventions, including cardiac electrophysiology procedures.
The company said the system would be shown at the European Society of Cardiology congress 2026 in Munich from August 28 to 31, 2026, and was commercially available in Conformité Européenne-marked regions.
Imricor said certain configurations were commercially available in the US.
Imricor said additional configurations were expected to become available in the US and other geographies, subject to applicable regulatory clearances.
Earlier this year, the company said it had US Food and Drug Administration 510(k) clearance for its Vision-MR diagnostic catheter and Northstar mapping and guidance system; and later, filed for clearance for its Navtrac and Navtrac-MR steerable cardiac catheter introducers (BD: Jan 18, 29, Jul 20, 2026).
Imricor executive chair Steve Wedan said "with interventional MR, the idea is not to move procedures into diagnostic MRI suites, but rather to bring MR imaging into the procedure room".
Imricor was up four cents or 2.1 percent to $1.97.

MEMPHASYS

Memphasys says it has Thai Food and Drug Administration approval to begin commercial sale of its Felix sperm separation system for in-vitro fertilization.
Last month, Memphasys said it had a three-year, minimum $430,500 distribution agreement with Bangkok's IVF Envimed Co for its Felix sperm separation system in Thailand, beginning on receipt of Thai FDA regulatory approval (BD: Jul 1, 2026).
Today, the company said the approval allowed it to begin commercial sales under its distribution agreement with IVF Envimed Co.
Memphasys said IVF Envimed had a received positive clinic response "driven by the potential clinical benefits of Felix, including improved embryo utilization and reduced sperm DNA fragmentation, together with its six-minute, simple and standardized sperm preparation process".
The company said IVF Envimed had "placed an additional order for 100 Felix cartridges and three paid consoles … in addition to the initial order of 100 cartridges and three consoles placed when the agreement was signed".
Memphasys was up 0.05 cents or 9.1 percent to 0.5 cents with 35.0 million shares traded.

PATRYS

Patrys says it has approval for a phase Ia trial of RLS-2202 injectable quetiapine in healthy volunteers.
Last year, Patrys said it would acquire Perth's Reliis Pty Ltd and its injectable quetiapine for delirium (BD: Nov 26, 2025).
Today, Patrys said the study would assess the safety, tolerability and pharmaco-kinetics of RLS-2202 in healthy volunteers and generate "important dosing information to inform subsequent stages of clinical development".
The company did not disclose the number of participants expected to be enrolled.
Patrys was up 0.1 cents or 3.3 percent to 3.1 cents.

PERCHERON THERAPEUTICS

Percheron says with Vanderbilt Health it will conduct an investigator-sponsored 38-patient trial of HMBD-002 in acute myeloid leukaemia and myelodysplastic syndrome.
Percheron said the Nashville, Tennessee-based Vanderbilt Health would lead a multi-centre trial of HMBD-002 with standard-of-care treatments azacitidine and venetoclax for high-risk acute myeloid leukaemia and myelodysplastic syndrome, forms of blood cancer.
Last year, the company said it had licenced Singapore's Hummingbird Bioscience's HMBD-002 for cancer (BD: Jun 26, 2025).
Today, Percheron said it would provide a grant to support the study, as well as study drug and technical assistance.
The company said it would "have full access to any trial data, which the company may use to inform future clinical trials, regulatory interactions, and partnering discussions".
Percheron said it continued "to advance discussions … to identify additional patient populations in which HMBD-002 may be investigated".
Percheron managing-director Dr James Garner said the company hoped "to see recruitment commence [by 2027]".
Separately, the company requested a trading halt pending an announcement on a capital raising to fund the investigator-sponsored study with Vanderbilt Health.
Trading will resume on September 1, 2026, or on an earlier announcement.
Percheron last traded at 0.5 cents.

AMPLIA THERAPEUTICS

Amplia says its annual general meeting has approved all resolutions with up-to 22.37 percent opposition to the 10 percent placement facility.
Last month, Amplia said shareholders investors would vote to increase the director fee pool by 150 percent and issue 2,830,629 zero exercise price options to its managing-director and board (BD: Jul 28, 2026).
Today, the company said the 10 percent placement facility was opposed by 32,704,132 votes (22.37%), with 113,485,982 votes (77.63%) in favor.
Amplia said all other resolutions were passed by more than 99.08 percent of the meeting.
According to its most recent notice, Amplia had 513,312,014 shares on issue, meaning that the votes against the placement facility amounted to about 6.4 percent of the company, sufficient to requisition extraordinary general meetings.
Amplia fell half a cent or 3.3 percent to 14.5 cents with 1.3 million shares traded.

COCHLEAR

Brisbane's Pinnacle Investment Management Group says it has become a substantial shareholder in Cochlear with 3,297,233 shares, or 5.04 percent of the company.
Pinnacle said it bought and sold shares between April 29 and August 24, 2026, with the largest purchase 93,986 shares on May 21 for $9,085,298, or $96.67 a share.
Cochlear fell $1.66 or 1.2 percent to $136.10 with 443,821 shares traded.

IMUGENE

Sydney's Washington H Soul Pattinson says it has become a substantial shareholder in Imugene through its more than 20 percent holding in Pengana Capital Group.
Yesterday, Pengana Capital Group said it became a substantial shareholder in Imugene with 31,540,076 shares, or 6.44 percent of the company. (BD: Aug 28, 2026).
Imugene fell 0.1 cents or 1.4 percent to seven cents with 2.3 million shares traded.

GENETIC SIGNATURES

Melbourne's Mercer Investments Australia says it has ceased its substantial shareholding in Genetic Signatures and retained 9,853,619 shares (4.338%).
Mercer said that between May 5 and August 3 it bought shares at prices from 5.63 cents to 8.0 cents a share and sold shares at 8.0 cents a share on May 14 and August 24, 2026.
Genetic Signatures was up 0.2 cents or 2.6 percent to eight cents.

NYRADA

Nyrada says Mark Azzi has increased his substantial shareholding from 25,568,254 Chess depository interests (CDIs) (10.35%) to 28,326,504 CDIs (11.44%).
Nyrada was up nine cents or 12.2 percent to 83 cents with 1.2 million shares traded.